{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T04:43:06Z","timestamp":1791434586051,"version":"4.3.3"},"reference-count":132,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007311","name":"Deutsche Kinderkrebsstiftung","doi-asserted-by":"publisher","award":["DKS 2021.11"],"award-info":[{"award-number":["DKS 2021.11"]}],"id":[{"id":"10.13039\/501100007311","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007311","name":"Deutsche Kinderkrebsstiftung","doi-asserted-by":"publisher","award":["DKS 2024.16"],"award-info":[{"award-number":["DKS 2024.16"]}],"id":[{"id":"10.13039\/501100007311","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.ctrv.2025.102942","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T06:24:47Z","timestamp":1744871087000},"page":"102942","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Targeting pediatric adrenocortical carcinoma: Molecular insights and emerging therapeutic strategies"],"prefix":"10.1016","volume":"136","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4577-0503","authenticated-orcid":false,"given":"Michaela","family":"Kuhlen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Schmutz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Kunstreich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antje","family":"Redlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Claus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 4","key":"10.1016\/j.ctrv.2025.102942_b0005","article-title":"Adrenocortical tumours in children and adolescents: The EXPeRT\/PARTNER diagnostic and therapeutic recommendations","volume":"68","author":"Virgone","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ctrv.2025.102942_b0010","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15010225","article-title":"Outcome for Pediatric Adreno-Cortical Tumors Is Best Predicted by the COG Stage and Five-Item Microscopic Score-Report from the German MET Studies","volume":"15","author":"Kuhlen","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctrv.2025.102942_b0015","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.jpedsurg.2014.03.006","article-title":"Adrenocortical tumors in Italian children: analysis of clinical characteristics and P53 status. Data from the national registries","volume":"49","author":"Dall'Igna","year":"2014","journal-title":"J Pediatr Surg"},{"key":"10.1016\/j.ctrv.2025.102942_b0020","doi-asserted-by":"crossref","unstructured":"Siegel DA, King J, Tai E, Buchanan N, Ajani UA, Li J. Cancer incidence rates and trends among children and adolescents in the United States, 2001-2009. Pediatrics. 2014;134:e945-55.","DOI":"10.1542\/peds.2013-3926"},{"key":"10.1016\/j.ctrv.2025.102942_b0025","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/pbc.20318","article-title":"Biology, clinical characteristics, and management of adrenocortical tumors in children","volume":"45","author":"Rodriguez-Galindo","year":"2005","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ctrv.2025.102942_b0030","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.jpedsurg.2013.02.017","article-title":"Predictors of survival in pediatric adrenocortical carcinoma: a Surveillance, Epidemiology, and End Results (SEER) program study","volume":"48","author":"McAteer","year":"2013","journal-title":"J Pediatr Surg"},{"key":"10.1016\/j.ctrv.2025.102942_b0035","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1200\/JCO.2004.08.085","article-title":"Clinical and outcome characteristics of children with adrenocortical tumors: a report from the International Pediatric Adrenocortical Tumor Registry","volume":"22","author":"Michalkiewicz","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102942_b0040","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgae073","article-title":"The endocrine phenotype induced by paediatric adrenocortical tumours is age- and sex-dependent","author":"Kunstreich","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ctrv.2025.102942_b0045","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1200\/JCO.2017.74.2460","article-title":"Identification of Clinical and Biologic Correlates Associated With Outcome in Children With Adrenocortical Tumors Without Germline TP53 Mutations: A St Jude Adrenocortical Tumor Registry and Children's Oncology Group Study","volume":"35","author":"Pinto","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102942_b0050","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1200\/JCO.2013.52.6863","article-title":"Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a children's oncology group study","volume":"33","author":"Wasserman","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102942_b0055","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26368","article-title":"Outcome and prognostic factors in high-risk childhood adrenocortical carcinomas: A report from the European Cooperative Study Group on Pediatric Rare Tumors (EXPeRT)","volume":"64","author":"Cecchetto","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ctrv.2025.102942_b0060","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28836","article-title":"Clinical prognostic factors in pediatric adrenocortical tumors: A meta-analysis","volume":"68","author":"Zambaiti","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ctrv.2025.102942_b0065","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28086","article-title":"Exploring heterogeneity of adrenal cortical tumors in children: The French pediatric rare tumor group (Fracture) experience","volume":"67","author":"Picard","year":"2020","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ctrv.2025.102942_b0070","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1200\/JCO.20.02871","article-title":"Treatment of Pediatric Adrenocortical Carcinoma With Surgery, Retroperitoneal Lymph Node Dissection, and Chemotherapy: The Children's Oncology Group ARAR0332 Protocol","volume":"39","author":"Rodriguez-Galindo","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102942_b0075","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1530\/ERC-22-0146","article-title":"Key factors for effective mitotane therapy in children with adrenocortical carcinoma","volume":"29","author":"Kuhlen","year":"2022","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ctrv.2025.102942_b0080","article-title":"Bridging molecular advancements and clinical challenges in pediatric oncology","author":"Kuhlen","year":"2024","journal-title":"World J Pediatr"},{"key":"10.1016\/j.ctrv.2025.102942_b0085","doi-asserted-by":"crossref","first-page":"6302","DOI":"10.1038\/ncomms7302","article-title":"Genomic landscape of paediatric adrenocortical tumours","volume":"6","author":"Pinto","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.ctrv.2025.102942_b0090","article-title":"DNA Methylation Profiling Reveals Prognostically Significant Groups in Pediatric Adrenocortical Tumors: A Report From the International Pediatric Adrenocortical Tumor Registry. JCO Precis","volume":"3","author":"Clay","year":"2019","journal-title":"Oncol"},{"key":"10.1016\/j.ctrv.2025.102942_b0095","unstructured":"Fincke V, Lo\u00dfner M, Sax I, Mucha M, Wudy S, Vokuhl C, et al. Investigating Single-Cell Transcriptomics to Navigate the Complexity of Pediatric Adrenocortical Tumors: Implications for Development, Prognosis, and Therapeutic Approaches. Pediatric Blood & Cancer. 2024;71:e31444; O271\/#1814."},{"key":"10.1016\/j.ctrv.2025.102942_b0100","unstructured":"Lo\u00dfner M, Fincke V, Sax I, Mucha M, Wudy S, Vokuhl C, et al. Molecular Characterisation of Pediatric Adrenocortical Tumors Reveals Clinically Relevant Subgroups. Pediatric Blood & Cancer. 2024;71:e31444; O269\/#1886."},{"key":"10.1016\/j.ctrv.2025.102942_b0105","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1007\/s13577-022-00778-2","article-title":"MicroRNA-149-3p expression correlates with outcomes of adrenocortical tumor patients and affects proliferation and cell cycle progression of H295A adrenocortical cancer cell line","volume":"35","author":"da Silva","year":"2022","journal-title":"Hum Cell"},{"key":"10.1016\/j.ctrv.2025.102942_b0110","doi-asserted-by":"crossref","first-page":"4666","DOI":"10.1158\/0008-5472.CAN-09-3970","article-title":"Regulation of insulin-like growth factor-mammalian target of rapamycin signaling by microRNA in childhood adrenocortical tumors","volume":"70","author":"Doghman","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2025.102942_b0115","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29553","article-title":"MicroRNA expression profile predicts prognosis of pediatric adrenocortical tumors","volume":"69","author":"Veronez","year":"2022","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ctrv.2025.102942_b0120","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/s41419-020-03205-2","article-title":"Long noncoding RNA ASB16-AS1 inhibits adrenocortical carcinoma cell growth by promoting ubiquitination of RNA-binding protein HuR","volume":"11","author":"Long","year":"2020","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.ctrv.2025.102942_b0125","doi-asserted-by":"crossref","first-page":"99","DOI":"10.7150\/jgen.22060","article-title":"Small Non-coding RNA Abundance in Adrenocortical Carcinoma: A Footprint of a Rare Cancer","volume":"5","author":"Koduru","year":"2017","journal-title":"J Genomics"},{"key":"10.1016\/j.ctrv.2025.102942_b0130","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1126\/science.1978757","article-title":"Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms","volume":"250","author":"Malkin","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.ctrv.2025.102942_b0140","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1200\/JCO.2014.59.5728","article-title":"Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers","volume":"33","author":"Bougeard","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102942_b0135","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.cancergen.2012.06.008","article-title":"Li-Fraumeni syndrome: report of a clinical research workshop and creation of a research consortium","volume":"205","author":"Mai","year":"2012","journal-title":"Cancer Genet"},{"key":"10.1016\/j.ctrv.2025.102942_b0145","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/humu.21151","article-title":"Detailed haplotype analysis at the TP53 locus in p.R337H mutation carriers in the population of Southern Brazil: evidence for a founder effect","volume":"31","author":"Garritano","year":"2010","journal-title":"Hum Mutat"},{"key":"10.1016\/j.ctrv.2025.102942_b0150","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.canlet.2005.12.039","article-title":"The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families","volume":"245","author":"Achatz","year":"2007","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ctrv.2025.102942_b0155","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/nrendo.2017.166","article-title":"Expert consensus document: Clinical and molecular diagnosis, screening and management of Beckwith-Wiedemann syndrome: an international consensus statement","volume":"14","author":"Brioude","year":"2018","journal-title":"Nat Rev Endocrinol"},{"issue":"142\u20139","key":"10.1016\/j.ctrv.2025.102942_b0160","first-page":"e1","article-title":"Cancer Risk in Beckwith-Wiedemann Syndrome: A Systematic Review and Meta-Analysis Outlining a Novel (Epi)Genotype Specific Histotype Targeted Screening Protocol","volume":"176","author":"Mussa","year":"2016","journal-title":"J Pediatr"},{"key":"10.1016\/j.ctrv.2025.102942_b0165","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1002\/ajmg.a.37801","article-title":"Phenotype, cancer risk, and surveillance in Beckwith-Wiedemann syndrome depending on molecular genetic subgroups","volume":"170","author":"Maas","year":"2016","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.ctrv.2025.102942_b0170","doi-asserted-by":"crossref","first-page":"5133","DOI":"10.1158\/1078-0432.CCR-10-1497","article-title":"Inactivation of the APC gene is constant in adrenocortical tumors from patients with familial adenomatous polyposis but not frequent in sporadic adrenocortical cancers","volume":"16","author":"Gaujoux","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2025.102942_b0175","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1097\/DCR.0000000000001008","article-title":"Characteristics of Adrenal Masses in Familial Adenomatous Polyposis","volume":"61","author":"Shiroky","year":"2018","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.ctrv.2025.102942_b0185","unstructured":"Pieterman CRC, van Leeuwaarde RS, van den Broek MFM, van Nesselrooij BPM, Valk GD. Multiple Endocrine Neoplasia Type 1. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, et al., editors. Endotext. South Dartmouth (MA)2000."},{"key":"10.1016\/j.ctrv.2025.102942_b0190","article-title":"Beyond the three P's: adrenal involvement in MEN1","volume":"31","author":"Clemente-Gutierrez","year":"2024","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ctrv.2025.102942_b0195","doi-asserted-by":"crossref","first-page":"4041","DOI":"10.1210\/jcem.86.9.7903","article-title":"Clinical and molecular features of the Carney complex: diagnostic criteria and recommendations for patient evaluation","volume":"86","author":"Stratakis","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ctrv.2025.102942_b0200","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jsbmb.2017.09.003","article-title":"The art of measuring steroids: Principles and practice of current hormonal steroid analysis","volume":"179","author":"Wudy","year":"2018","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.ctrv.2025.102942_b0205","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1530\/EJE-18-0782","article-title":"Plasma steroid metabolome profiling for the diagnosis of adrenocortical carcinoma","volume":"180","author":"Schweitzer","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ctrv.2025.102942_b0210","doi-asserted-by":"crossref","DOI":"10.3390\/metabo14010020","article-title":"Early Detection of Recurrence and Progress Using Serum Steroid Profiling by LC-MS\/MS in Patients with Adrenocortical Carcinoma","volume":"14","author":"Kimpel","year":"2023","journal-title":"Metabolites"},{"issue":"Suppl 1","key":"10.1016\/j.ctrv.2025.102942_b0215","doi-asserted-by":"crossref","first-page":"194s","DOI":"10.1016\/S0753-3322(00)80043-8","article-title":"Urinary steroid profile in adrenocortical tumors","volume":"54","author":"Kikuchi","year":"2000","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.ctrv.2025.102942_b0220","doi-asserted-by":"crossref","first-page":"3775","DOI":"10.1210\/jc.2011-1565","article-title":"Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors","volume":"96","author":"Arlt","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ctrv.2025.102942_b0225","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1007\/s10517-019-04597-8","article-title":"Gas Chromatography-Mass Spectrometry Analysis of Urinary Steroid Metabolomics for Detection of Early Signs of Adrenal Neoplasm Malignancy in Patients with Cushing's Syndrome","volume":"167","author":"Velikanova","year":"2019","journal-title":"Bull Exp Biol Med"},{"key":"10.1016\/j.ctrv.2025.102942_b0230","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S2213-8587(20)30218-7","article-title":"Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study","volume":"8","author":"Bancos","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ctrv.2025.102942_b0235","doi-asserted-by":"crossref","first-page":"e307","DOI":"10.1210\/clinem\/dgz141","article-title":"Urine Steroid Metabolomics as a Novel Tool for Detection of Recurrent Adrenocortical Carcinoma","volume":"105","author":"Chortis","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ctrv.2025.102942_b0240","unstructured":"Hartmann M, Pons-K\u00fchnemann J, Kunstreich M, Redlich A, Vorwerk P, Kuhlen M, et al. Detection and differentiation of adrenocortical tumors (ACTs) in children by gas chromatography- mass spectrometry (GC-MS) based urinary steroid metabotyping. Hormone Research in Paediatrics. 2024;97:1-736, Abstr FC8.2."},{"key":"10.1016\/j.ctrv.2025.102942_b0245","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.mce.2011.09.040","article-title":"Differences in the molecular mechanisms of adrenocortical tumorigenesis between children and adults","volume":"351","author":"Faria","year":"2012","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.ctrv.2025.102942_b0250","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/s41574-019-0221-7","article-title":"Adrenocortical carcinoma - towards genomics guided clinical care","volume":"15","author":"Crona","year":"2019","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.ctrv.2025.102942_b0255","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1093\/oncolo\/oyae029","article-title":"Adrenocortical Carcinomas: Molecular Pathogenesis, Treatment Options, and Emerging Immunotherapy and Targeted Therapy Approaches","volume":"29","author":"Chukkalore","year":"2024","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2025.102942_b0260","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","article-title":"Combination chemotherapy in advanced adrenocortical carcinoma","volume":"366","author":"Fassnacht","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2025.102942_b0265","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.2147\/CMAR.S348725","article-title":"Pediatric Adrenocortical Carcinoma: The Nuts and Bolts of Diagnosis and Treatment and Avenues for Future Discovery","volume":"16","author":"O'Neill","year":"2024","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.ctrv.2025.102942_b0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.05.006","article-title":"Outcome of adrenocortical carcinoma patients included in early phase clinical trials: Results from the French network ENDOCAN-COMETE","volume":"189","author":"Hescot","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2025.102942_b0275","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-18-0608","article-title":"European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors","volume":"179","author":"Fassnacht","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ctrv.2025.102942_b0280","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13215266","article-title":"Adrenocortical Carcinoma in Childhood: A Systematic Review","volume":"13","author":"Riedmeier","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctrv.2025.102942_b0285","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S2213-8587(23)00193-6","article-title":"Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study","volume":"11","author":"Terzolo","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ctrv.2025.102942_b0290","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s12020-021-02874-z","article-title":"Different management of adrenocortical carcinoma in children compared to adults: is it time to share guidelines?","volume":"74","author":"Grisanti","year":"2021","journal-title":"Endocrine"},{"key":"10.1016\/j.ctrv.2025.102942_b0295","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvae163.144","article-title":"7959 Combination Therapy Of Multi-Targeted Tyrosine Kinase Inhibitors And Immune Checkpoint Inhibitors In Advanced Adrenocortical Carcinoma","volume":"8","author":"Yaylaci Mert","year":"2024","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.ctrv.2025.102942_b0300","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1470-2045(24)00095-0","article-title":"Cabozantinib monotherapy for advanced adrenocortical carcinoma: a single-arm, phase 2 trial","volume":"25","author":"Campbell","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2025.102942_b0305","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1055\/s-0032-1327579","article-title":"Systemic treatment of adrenocortical carcinoma in children: data from the German GPOH-MET 97 trial","volume":"224","author":"Redlich","year":"2012","journal-title":"Klin Padiatr"},{"key":"10.1016\/j.ctrv.2025.102942_b0310","doi-asserted-by":"crossref","DOI":"10.1093\/ejendo\/lvae038","article-title":"International consensus on mitotane treatment in pediatric patients with adrenal cortical tumors: Indications, therapy, and management of adverse effects","author":"Riedmeier","year":"2024","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ctrv.2025.102942_b0315","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1097\/00000478-200307000-00001","article-title":"Adrenal cortical neoplasms in the pediatric population: a clinicopathologic and immunophenotypic analysis of 83 patients","volume":"27","author":"Wieneke","year":"2003","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ctrv.2025.102942_b0320","article-title":"Refractory and relapsed paediatric ACC in the MET studies \u2013 A challenging situation necessitating novel diagnostic and therapeutic concepts. EJC Paediatric","volume":"1","author":"Kuhlen","year":"2023","journal-title":"Oncology"},{"key":"10.1016\/j.ctrv.2025.102942_b0325","first-page":"56","article-title":"Radiotherapy for pediatric adrenocortical carcinoma - Review of the literature","volume":"35","author":"Wiegering","year":"2022","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.ctrv.2025.102942_b0330","doi-asserted-by":"crossref","unstructured":"Kuhlen MS, C; Fuchs, J; Kunstreich, M; Johann, P; Claus, R; Fr\u00fchwald, M; Vorwerk, P; Redlich, A. Oligo- and polymetastatic paediatric adrenocortical carcinoma \u2013 distinct conditions necessitating different treatment approaches? Presented at European Congress of Endocrinology 2024, Stockholm, Sweden. Presented at Society for Endocrinology 2024, Stockholm, Sweden. Endocrine Abstracts. 2024; Volume 99:EP557.","DOI":"10.1530\/endoabs.99.EP557"},{"key":"10.1016\/j.ctrv.2025.102942_b0335","doi-asserted-by":"crossref","first-page":"4296","DOI":"10.3390\/cancers15174296","article-title":"Locally Advanced Adrenocortical Carcinoma in Children and Adolescents\u2014Enigmatic and Challenging Cases","volume":"15","author":"Kuhlen","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.ctrv.2025.102942_b0340","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15112873","article-title":"Preclinical Models of Adrenocortical Cancer","volume":"15","author":"Sedlack","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctrv.2025.102942_b0345","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.coemr.2019.08.009","article-title":"Contemporary preclinical human models of adrenocortical carcinoma","volume":"8","author":"Pinto","year":"2019","journal-title":"Curr Opin Endocr Metab Res"},{"key":"10.1016\/j.ctrv.2025.102942_b0350","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.mce.2011.08.041","article-title":"Human adrenocortical carcinoma cell lines","volume":"351","author":"Wang","year":"2012","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.ctrv.2025.102942_b0355","doi-asserted-by":"crossref","DOI":"10.3390\/cells11091439","article-title":"A Comprehensive Investigation of Steroidogenic Signaling in Classical and New Experimental Cell Models of Adrenocortical Carcinoma","volume":"11","author":"Sigala","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.ctrv.2025.102942_b0360","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.1210\/jc.2018-01348","article-title":"Targeted Molecular Analysis in Adrenocortical Carcinomas: A Strategy Toward Improved Personalized Prognostication","volume":"103","author":"Lippert","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ctrv.2025.102942_b0365","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14112721","article-title":"Targeted Therapy for Adrenocortical Carcinoma: A Genomic-Based Search for Available and Emerging Options","volume":"14","author":"Hescheler","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctrv.2025.102942_b0370","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ejca.2017.06.023","article-title":"Mutant p53 as a target for cancer treatment","volume":"83","author":"Duffy","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2025.102942_b0375","doi-asserted-by":"crossref","DOI":"10.3390\/cancers9120172","article-title":"PRIMA-1 and PRIMA-1(Met) (APR-246): From Mutant\/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies","volume":"9","author":"Perdrix","year":"2017","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctrv.2025.102942_b0380","doi-asserted-by":"crossref","DOI":"10.1080\/13543776.2024.2419836","article-title":"An update patent review of MDM2-p53 interaction inhibitors (2019-2023)","author":"Twarda-Clapa","year":"2024","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.ctrv.2025.102942_b0385","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1124\/pharmrev.123.001026","article-title":"MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future","volume":"76","author":"Wang","year":"2024","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.ctrv.2025.102942_b0390","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s12935-024-03356-8","article-title":"MDM2: current research status and prospects of tumor treatment","volume":"24","author":"Yao","year":"2024","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.ctrv.2025.102942_b0395","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1530\/ERC-15-0426","article-title":"IGF2 and IGF1R in pediatric adrenocortical tumors: roles in metastasis and steroidogenesis","volume":"23","author":"Peixoto Lira","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ctrv.2025.102942_b0400","doi-asserted-by":"crossref","first-page":"3524","DOI":"10.1210\/jc.2008-0065","article-title":"Expression of insulin-like growth factor-II and its receptor in pediatric and adult adrenocortical tumors","volume":"93","author":"Almeida","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ctrv.2025.102942_b0405","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1210\/jc.2008-1456","article-title":"Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma","volume":"94","author":"Barlaskar","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ctrv.2025.102942_b0410","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1158\/1078-0432.CCR-14-0265","article-title":"Phase I study of intermittent oral dosing of the insulin-like growth factor-1 and insulin receptors inhibitor OSI-906 in patients with advanced solid tumors","volume":"21","author":"Jones","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2025.102942_b0415","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S1470-2045(15)70081-1","article-title":"Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study","volume":"16","author":"Fassnacht","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2025.102942_b0420","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/pbc.24605","article-title":"Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children's Oncology Group","volume":"61","author":"Weigel","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ctrv.2025.102942_b0425","unstructured":"Houghton P. Targeting the IGF-1\/mTOR pathway. Clinical Cancer Research. 2014;14:PL05-3-PL-3."},{"key":"10.1016\/j.ctrv.2025.102942_b0430","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.tem.2018.07.003","article-title":"mTORC1 and IRS1: Another Deadly Kiss","volume":"29","author":"Ardestani","year":"2018","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.ctrv.2025.102942_b0435","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ctrv.2017.11.002","article-title":"Targeting the Wnt\/beta-catenin pathway in cancer: Update on effectors and inhibitors","volume":"62","author":"Krishnamurthy","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2025.102942_b0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.102544","article-title":"Molecular docking-aided identification of small molecule inhibitors targeting beta-catenin-TCF4 interaction","volume":"24","author":"Low","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.ctrv.2025.102942_b0445","doi-asserted-by":"crossref","first-page":"22825","DOI":"10.18632\/oncotarget.15221","article-title":"Rottlerin as a novel chemotherapy agent for adrenocortical carcinoma","volume":"8","author":"Zhu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2025.102942_b0450","doi-asserted-by":"crossref","first-page":"84634","DOI":"10.18632\/oncotarget.12382","article-title":"Unraveling the expression of the oncogene YAP1, a Wnt\/beta-catenin target, in adrenocortical tumors and its association with poor outcome in pediatric patients","volume":"7","author":"Abduch","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2025.102942_b0455","doi-asserted-by":"crossref","DOI":"10.3390\/ph17070949","article-title":"Why Is Wnt\/beta-Catenin Not Yet Targeted in Routine Cancer Care?","volume":"17","author":"de Pellegars-Malhortie","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.ctrv.2025.102942_b0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2024.189195","article-title":"Belling the \u201ccat\u201d: Wnt\/beta-catenin signaling and its significance in future cancer therapies","volume":"1879","author":"Goyal","year":"2024","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"10.1016\/j.ctrv.2025.102942_b0465","doi-asserted-by":"crossref","first-page":"E1209","DOI":"10.1210\/jc.2013-4098","article-title":"Sonic hedgehog signaling is active in human adrenal cortex development and deregulated in adrenocortical tumors","volume":"99","author":"Gomes","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ctrv.2025.102942_b0470","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.ando.2022.07.118","article-title":"Sonic Hedgehog signaling pathway is expressed in normal human adrenal cortices and up-regulated in adrenocortical carcinomas","volume":"83","author":"Camponova","year":"2022","journal-title":"Ann Endocrinol"},{"key":"10.1016\/j.ctrv.2025.102942_b0475","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1158\/1078-0432.CCR-10-2745","article-title":"Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors","volume":"17","author":"LoRusso","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2025.102942_b0480","doi-asserted-by":"crossref","unstructured":"Sun N-Y, Kumar S, Weiner A, Kim YS, Mendoza A, Nguyen R, et al. Targeting DLK1, a Notch ligand, with an antibody-drug conjugate in adrenocortical carcinoma [abstract]. Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1. 2024;84.","DOI":"10.1158\/1538-7445.AM2024-6573"},{"key":"10.1016\/j.ctrv.2025.102942_b0485","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/pbc.24653","article-title":"Spindle assembly checkpoint gene expression in childhood adrenocortical tumors (ACT): Overexpression of Aurora kinases A and B is associated with a poor prognosis","volume":"60","author":"Borges","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ctrv.2025.102942_b0490","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2021.111243","article-title":"Inhibition of Aurora kinase A activity enhances the antitumor response of beta-catenin blockade in human adrenocortical cancer cells","volume":"528","author":"Maria","year":"2021","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.ctrv.2025.102942_b0495","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s10637-016-0358-3","article-title":"The aurora kinase inhibitor VX-680 shows anti-cancer effects in primary metastatic cells and the SW13 cell line","volume":"34","author":"Pezzani","year":"2016","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ctrv.2025.102942_b0500","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.667798","article-title":"Effects of Sorafenib, a Tyrosin Kinase Inhibitor, on Adrenocortical Cancer","volume":"12","author":"Cerquetti","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.ctrv.2025.102942_b0505","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1210\/jc.2012-1419","article-title":"Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial","volume":"97","author":"Kroiss","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ctrv.2025.102942_b0510","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1055\/a-1453-0806","article-title":"Advanced Adrenocortical Carcinoma: Current Perspectives on Medical Treatment","volume":"53","author":"Araujo","year":"2021","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.ctrv.2025.102942_b0515","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27077","article-title":"A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology Group","volume":"65","author":"Chuk","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ctrv.2025.102942_b0520","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1002\/jcb.27451","article-title":"MAPK\/ERK pathway inhibition is a promising treatment target for adrenocortical tumors","volume":"120","author":"Pereira","year":"2019","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.ctrv.2025.102942_b0525","article-title":"Pharmacogenomic analysis in adrenocortical carcinoma reveals genetic features associated with mitotane sensitivity and potential therapeutics","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.ctrv.2025.102942_b0530","doi-asserted-by":"crossref","unstructured":"Mishra P, Shen M, Hall M, Zhang Y-Q, Nilubol N. RF07 | PSUN356 Synergistic Combination of HSP90 and PI3K inhibitors in Adrenocortical Cancer. Journal of the Endocrine Society. 2022;6:A895-A.","DOI":"10.1210\/jendso\/bvac150.1854"},{"key":"10.1016\/j.ctrv.2025.102942_b0535","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40169-015-0080-3","article-title":"Targeting polo-like kinase 1, a regulator of p53, in the treatment of adrenocortical carcinoma","volume":"5","author":"Bussey","year":"2016","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.ctrv.2025.102942_b0540","article-title":"PLK1 inhibitors as a new targeted treatment for adrenocortical carcinoma. Endocr","volume":"13","author":"Warmington","year":"2024","journal-title":"Connect"},{"key":"10.1016\/j.ctrv.2025.102942_b0545","doi-asserted-by":"crossref","first-page":"A129","DOI":"10.1210\/jendso\/bvab048.261","article-title":"Efficacy of Treatment With PARP Inhibitor and Immunotherapy for Aggressive Adrenocortical Carcinomawith Cushing\u2019s Syndrome Refractory to Treatment With EDP Chemotherapy and Mitotane","volume":"5","author":"Greb","year":"2021","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.ctrv.2025.102942_b0550","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1186\/s12885-022-10319-7","article-title":"The potential of PARP as a therapeutic target across pediatric solid malignancies","volume":"23","author":"Keller","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2025.102942_b0555","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.18632\/aging.101356","article-title":"A hypothesis-driven approach identifies CDK4 and CDK6 inhibitors as candidate drugs for treatments of adrenocortical carcinomas","volume":"9","author":"Hadjadj","year":"2017","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.ctrv.2025.102942_b0560","doi-asserted-by":"crossref","unstructured":"Macy ME, Mody R, Reid JM, Piao J, Saguilig L, Alonzo TA, et al. Palbociclib in solid tumor patients with genomic alterations in the cyclin D-CDK4\/6-INK4a-Rb pathway: Results from NCI-COG pediatric MATCH trial Arm I (APEC1621I). Journal of Clinical Oncology. 2023;41:10006-.","DOI":"10.1200\/JCO.2023.41.16_suppl.10006"},{"key":"10.1016\/j.ctrv.2025.102942_b0565","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1158\/1535-7163.MCT-24-0369","article-title":"Separable Cell Cycle Arrest and Immune Response Elicited through Pharmacological CDK4\/6 and MEK Inhibition in RASmut Disease Models","volume":"23","author":"Wu","year":"2024","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ctrv.2025.102942_b0570","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.surg.2021.04.049","article-title":"Identification of novel lipid metabolic biomarkers associated with poor adrenocortical carcinoma prognosis using integrated bioinformatics","volume":"171","author":"Subramanian","year":"2022","journal-title":"Surgery"},{"key":"10.1016\/j.ctrv.2025.102942_b0575","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1197502","article-title":"Targeting sterol-O-acyltransferase 1 to disrupt cholesterol metabolism for cancer therapy","volume":"13","author":"Tu","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2025.102942_b0580","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1007\/s10637-020-00899-1","article-title":"A phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinoma","volume":"38","author":"Smith","year":"2020","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ctrv.2025.102942_b0585","doi-asserted-by":"crossref","first-page":"4594","DOI":"10.1210\/jc.2016-2414","article-title":"Antisecretive and Antitumor Activity of Abiraterone Acetate in Human Adrenocortical Cancer: A Preclinical Study","volume":"101","author":"Fiorentini","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ctrv.2025.102942_b0590","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1056\/NEJMoa063360","article-title":"Adjuvant mitotane treatment for adrenocortical carcinoma","volume":"356","author":"Terzolo","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2025.102942_b0595","first-page":"196","article-title":"Clinical utility of ketoconazole in cases of adrenocortical carcinoma","volume":"28","author":"Harinarayan","year":"1991","journal-title":"Indian J Cancer"},{"key":"10.1016\/j.ctrv.2025.102942_b0600","first-page":"229","article-title":"Use of ketoconazole in the treatment of a virilizing adrenocortical carcinoma","volume":"121","author":"Verhelst","year":"1989","journal-title":"Acta Endocrinol (Copenh)"},{"key":"10.1016\/j.ctrv.2025.102942_b0605","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1530\/EJE-14-0913","article-title":"Rapid control of severe neoplastic hypercortisolism with metyrapone and ketoconazole","volume":"172","author":"Corcuff","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ctrv.2025.102942_b0610","first-page":"201","article-title":"Pre-operative control of arterial hypertension using ketoconazole in pediatric patients with adrenocortical tumors","volume":"13","author":"Neto","year":"2000","journal-title":"J Pediatr Endocrinol Metab"},{"key":"10.1016\/j.ctrv.2025.102942_b0615","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24043585","article-title":"Steroidogenic Factor 1, a Goldilocks Transcription Factor from Adrenocortical Organogenesis to Malignancy","volume":"24","author":"Relav","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ctrv.2025.102942_b0620","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ando.2009.02.002","article-title":"A matter of dosage: SF-1 in adrenocortical development and cancer","volume":"70","author":"Doghman","year":"2009","journal-title":"Ann Endocrinol (Paris)"},{"key":"10.1016\/j.ctrv.2025.102942_b0625","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9030304","article-title":"Immunotherapy in Adrenocortical Carcinoma: Predictors of Response, Efficacy, Safety, and Mechanisms of Resistance","volume":"9","author":"Araujo-Castro","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.ctrv.2025.102942_b0630","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(19)30671-0","article-title":"Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial","volume":"21","author":"Geoerger","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2025.102942_b0635","article-title":"Abstract: 12485: Evaluating B7-H3-CAR T Cell Therapy In Preclinical Models Of Pediatric Adrenocortical Tumors","volume":"8","author":"Pinto","year":"2024","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.ctrv.2025.102942_b0640","doi-asserted-by":"crossref","unstructured":"R. E, Pinto EM, SaRebecca T, Epperly E, Pinto M, Santiago T, et al. Abstract 1197: B7-H3-CAR T cells for the treatment of pediatric adrenocortical carcinoma. Cancer Research. 2023;83:1197-.","DOI":"10.1158\/1538-7445.AM2023-1197"},{"key":"10.1016\/j.ctrv.2025.102942_b0645","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1210\/jcem.87.3.8331","article-title":"Association of H19 promoter methylation with the expression of H19 and IGF-II genes in adrenocortical tumors","volume":"87","author":"Gao","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ctrv.2025.102942_b0650","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1001\/archsurg.2009.292","article-title":"Antineoplastic effects of decitabine, an inhibitor of DNA promoter methylation, in adrenocortical carcinoma cells","volume":"145","author":"Suh","year":"2010","journal-title":"Arch Surg"},{"key":"10.1016\/j.ctrv.2025.102942_b0655","doi-asserted-by":"crossref","DOI":"10.3390\/ph17010025","article-title":"Radiopharmaceuticals for Treatment of Adrenocortical Carcinoma","volume":"17","author":"Michalski","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.ctrv.2025.102942_b0660","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/MOU.0000000000001040","article-title":"Adrenal functional imaging - which marker for which indication?","volume":"32","author":"Werner","year":"2022","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.ctrv.2025.102942_b0665","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00259-021-05477-y","article-title":"Novel CYP11B-ligand [(123\/131)I]IMAZA as promising theranostic tool for adrenocortical tumors: comprehensive preclinical characterization and first clinical experience","volume":"49","author":"Heinze","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225000647?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225000647?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T21:59:29Z","timestamp":1778536769000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737225000647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":132,"alternative-id":["S0305737225000647"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.102942","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting pediatric adrenocortical carcinoma: Molecular insights and emerging therapeutic strategies","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.102942","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102942"}}